Compare Amphastar Pharmaceuticals Inc (AMPH) vs Autozone Inc (AZO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Autozone Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Autozone Inc trades at $3,042 (market cap $50.09B). The key difference: Autozone Inc is far larger — about 58× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | AZO | |
|---|---|---|
Market Cap | $863.95M | $50.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $4.35K |
52-Week Low | $16.87 | $2.92K |
Enterprise Value | $1.26B | $62.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
AutoZone (AZO) trades at $3,127.29, up 1.88% recently, with a bullish technical signal and strong analyst support. Revenue grew to $18.94B in 2025, though net income margin dipped to 13.19%. The company maintains robust cash flow from operations and recently authorized a $1.5B stock buyback, signaling confidence. Key resistance lies near $3,160, with support at $3,063.
Outlook remains positive with 73% analyst buy ratings and a $3,730 consensus price target, implying ~19% upside. Risks include margin pressure from rising costs and competitive threats. Earnings beats in recent quarters support growth, but investors should monitor execution on international expansion and capex efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
